Chin augmentation is an often overlooked, yet frequently effective way to achieve facial harmony. For those who are looking to reap the rewards of enhancing their chin area but wish to avoid surgery, pharmaceutical company Allergan Aesthetics recently announced the FDA approval of Juvéderm Voluma XC. The product was approved for use in adults over the age of 21 and is the first and only filler to receive U.S. FDA approval for the augmentation of the chin region. In the U.S. pivotal study, Juvéderm Voluma XC was shown to be safe and effective, and the majority of patients reported high satisfaction through the one-year follow-up. "Due to its distinct gel properties and product profile, Juvéderm Voluma XC is uniquely suitable to address this need," says Carrie Strom, senior vice president of AbbVie and president of Global Allergan Aesthetics. "It's always rewarding when we can offer a safe and effective non-surgical alternative to patients. Addressing chin contour and shape is another way we are moving the market forward through our commitment to continued innovation."